Susquehanna Portfolio Strategies’s Kyverna Therapeutics KYTX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$240K	Buy	+27,846	New	+$232K	﹤0.01%	881

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Susquehanna Portfolio Strategies's KYTX Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Kyverna Therapeutics (KYTX) in Q1 2026: 27,846 shares worth $240K. The stake represents ﹤0.01% of the portfolio and ranks #881 among its holdings.

111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Susquehanna Portfolio Strategies held 27,846 shares of Kyverna Therapeutics worth $240K as of Q1 2026.
Kyverna Therapeutics was a new Susquehanna Portfolio Strategies position in Q1 2026.
Kyverna Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #881 holding.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.